Suppr超能文献

B细胞中的微小RNA:从正常分化到恶性肿瘤治疗

MicroRNAs in B-cells: from normal differentiation to treatment of malignancies.

作者信息

Marques Sara Correia, Laursen Maria Bach, Bødker Julie Støve, Kjeldsen Malene Krag, Falgreen Steffen, Schmitz Alexander, Bøgsted Martin, Johnsen Hans Erik, Dybkaer Karen

机构信息

Department of Haematology, Aalborg University Hospital, Aalborg, Denmark. Department of Clinical Medicine, Aarhus University, Denmark.

Department of Haematology, Aalborg University Hospital, Aalborg, Denmark.

出版信息

Oncotarget. 2015 Jan 1;6(1):7-25. doi: 10.18632/oncotarget.3057.

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that play important post-transcriptional regulatory roles in a wide range of biological processes. They are fundamental to the normal development of cells, and evidence suggests that the deregulation of specific miRNAs is involved in malignant transformation due to their function as oncogenes or tumor suppressors. We know that miRNAs are involved in the development of normal B-cells and that different B-cell subsets express specific miRNA profiles according to their degree of differentiation. B-cell-derived malignancies contain transcription signatures reminiscent of their cell of origin. Therefore, we believe that normal and malignant B-cells share features of regulatory networks controlling differentiation and the ability to respond to treatment. The involvement of miRNAs in these processes makes them good biomarker candidates. B-cell malignancies are highly prevalent, and the poor overall survival of patients with these malignancies demands an improvement in stratification according to prognosis and therapy response, wherein we believe miRNAs may be of great importance. We have critically reviewed the literature, and here we sum up the findings of miRNA studies in hematological cancers, from the development and progression of the disease to the response to treatment, with a particular emphasis on B-cell malignancies.

摘要

微小RNA(miRNA)是一类小的非编码RNA,在广泛的生物学过程中发挥重要的转录后调控作用。它们对于细胞的正常发育至关重要,并且有证据表明,特定miRNA的失调因其作为癌基因或肿瘤抑制因子的功能而参与恶性转化。我们知道miRNA参与正常B细胞的发育,并且不同的B细胞亚群根据其分化程度表达特定的miRNA谱。B细胞来源的恶性肿瘤包含与其起源细胞相似的转录特征。因此,我们认为正常和恶性B细胞共享控制分化的调控网络特征以及对治疗作出反应的能力。miRNA参与这些过程使其成为良好的生物标志物候选物。B细胞恶性肿瘤非常普遍,这些恶性肿瘤患者总体生存率低,需要根据预后和治疗反应改进分层,我们认为miRNA可能非常重要。我们对文献进行了严格审查,在此总结了miRNA在血液系统癌症中的研究结果,从疾病的发生发展到治疗反应,特别强调了B细胞恶性肿瘤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f75a/4381575/a78080af8a69/oncotarget-06-007-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验